

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **September 1, 2017**

**ONCOSEC MEDICAL INCORPORATED**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**000-54318**  
(Commission  
File Number)

**98-0573252**  
(I.R.S. Employer  
Identification No.)

**5820 Nancy Ridge Drive**  
**San Diego, California**  
(Address of principal executive offices)

**92121**  
(Zip Code)

Registrant's telephone number, including area code: **(855) 662-6732**

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.**

( d ) On September 1, 2017, the Board of Directors of OncoSec Medical Incorporated (the “Company”) appointed Dr. Annalisa M. Jenkins as a director on the Company’s Board of Directors and as a member of the Audit Committee and Nominating & Corporate Governance Committee of the Company’s Board of Directors, in each case effective as of September 5, 2017. The Company’s Board of Directors has determined that Dr. Jenkins qualifies as independent under applicable rules of the Nasdaq Stock Market.

Dr. Jenkins, M.B.B.S., F.R.C.P., age 52, has served as the president, chief executive officer and a director on the board of directors of Dimension Therapeutics since September 2014. Prior to joining Dimension Therapeutics, Dr. Jenkins served as Executive Vice President and Head of Global Research and Development at Merck Serono, where she also led Global Medical Affairs and Quality and was a member of its Pharmaceutical Executive Committee from 2013 to 2014. She also served as Executive Vice President Global Development and Medical Affairs from 2011 to 2013 at Merck Serono. Prior to this, Dr. Jenkins held several leadership roles at Bristol-Myers Squibb from 1997 to 2011, most recently serving as Senior Vice President and Head of Global Medical Affairs. Earlier in her career, Dr. Jenkins was a Medical Officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins is a member of the board of directors of Ardelyx, Inc., Biothera Pharmaceutical Inc., iOX Therapeutics Limited, MedCity and Vium (elected to executive chair in 2017) and previously served as a board member of Prosensa Holding N.V. (acquired by BioMarin Pharmaceutical) and Viventia Bio, Inc. (acquired by Eleven Bio). She also is a committee member of the Science Board to the U.S. Food and Drug Administration, serves on the board of the Center for Talent Innovation (U.K.) and is on the Advisory Panel of the Healthcare Businesswomen’s Association. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.

Dr. Jenkins’s compensation for her services as a director, including her services on all committees of the Company’s Board of Directors, will consist of annual cash compensation of \$50,000. In addition, upon her appointment as a director, Dr. Jenkins was granted a stock option award to purchase up to 100,000 shares of the Company’s common stock, which has an exercise price of \$0.979 and vests in equal monthly installments over a 12-month period subject to continued service as a director on each vesting date. Additionally, upon her appointment, the Company entered into an indemnification agreement with Dr. Jenkins in the same form as the indemnification agreements the Company has entered into with its other directors. In general, these indemnification agreements require the Company to indemnify a director to the fullest extent permitted by law against liabilities that may arise by reason of his or her service for the Company. Other than these arrangements, there are no arrangements or understandings between Dr. Jenkins and any other persons pursuant to which she was selected as a director of the Company. Dr. Jenkins is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission.

**Item 8.01 Other Events.**

On September 5, 2017, the Company issued a press release announcing the appointment of Dr. Jenkins as a director of the Company, a copy of which is attached as [Exhibit 99.1 hereto](#) and incorporated herein by reference.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ONCOSEC MEDICAL INCORPORATED**

Dated: September 5, 2017

By: /s/ Punit Dhillon

Name: Punit Dhillon

Title: President and Chief Executive Officer



## **OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors**

*Former Head of Global Research and Development for Merck Serono and Head of Global Medical Affairs of Bristol-Myers Squibb brings biopharma drug development, fundraising and M&A experience to OncoSec*

SAN DIEGO, September 5, 2017 — OncoSec Medical Incorporated (“OncoSec” or the “Company” (NASDAQ:ONCS)), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of **Annalisa Jenkins**, MBBS, FRCP, CEO of Dimension Therapeutics, Inc. (NASDAQ:DMTX), to its Board of Directors. Dr. Jenkins brings over 25 years of global industry experience to OncoSec’s Board of Directors with a wealth of knowledge in advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Her election to the Company’s Board is effective immediately.

“We are very pleased to have Dr. Jenkins join our Board as we believe her international biopharma drug development experience will be an asset to OncoSec as we advance our lead melanoma program and pursue collaborations with other industry leaders in oncology,” said Punit Dhillon, President and CEO of OncoSec. “Drawing on her years of experience in the biopharma industry, we believe Dr. Jenkins will provide new insights to our technology and business priorities as we continue to advance our broad clinical portfolio and achieve future growth objectives.”

“I believe OncoSec’s clinical program for ImmunoPulse® IL-12 can have a significant impact on how we approach cancer care by addressing a significant unmet need for melanoma patients that do not currently respond to anti-PD-1 treatments. In addition, I’m impressed with the Company’s commitment to advancing its innovative drug development approach, putting science and patients at the core of its mission,” said Dr. Jenkins. “I look forward to contributing to the Company’s advancement of its promising product candidates through clinical development.”

Prior to Dimension Therapeutics, Dr. Jenkins served as Executive Vice President and Head of Global Research and Development for Merck Serono, a global division of Merck KGaA focused on biopharmaceuticals. She also led Global Medical Affairs and Quality at Merck Serono and was a member of its Pharmaceutical Executive Committee. Dr. Jenkins also had a nearly 15-year career at Bristol-Myers Squibb, attaining the role of Senior Vice President and Head of Global Medical Affairs. She began her career as a Medical Officer with the British Royal Navy during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. Dr. Jenkins received an MBBS in Medicine from St. Bartholomew’s Hospital in the University of London and trained in cardiovascular medicine in the National Health Service (U.K.).

Currently, Dr. Jenkins serves as a director for several companies including: Ardelyx, Inc., Biothera Pharmaceutical Inc., iOX Therapeutics Limited, MedCity and Vium. She also is a committee member of the Science Board to the U.S. Food and Drug Administration, serves on the Board of the Center for Talent Innovation (U.K.) and is on the Advisory Panel of the Healthcare Businesswomen’s Association.

### **About OncoSec Medical Incorporated**

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors and has shown the potential to reach beyond the site of local treatment to initiate a systemic immune response. ImmunoPulse® IL-12, OncoSec’s lead program, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit [www.oncosec.com](http://www.oncosec.com).

---

## Cautionary Note Regarding Forward-Looking Statements

*This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements about OncoSec’s business strategies, including advancement of its lead melanoma program and its broader clinical portfolio and plans to pursue collaborations with industry partners, as well as the potential contributions and impact of new directors on these strategies. Forward-looking statements can be identified by words such as “can,” “may,” “will,” “suggest,” “look forward to,” “potential,” “understand,” and similar references to future periods.*

*Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause OncoSec’s results to differ materially and adversely from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: uncertainties inherent in pre-clinical studies and clinical trials, such as the substantial time, costs and unpredictability of such studies and trials, the ability to enroll patients in clinical trials and the risk of adverse events; unexpected new data, safety and technical issues; OncoSec’s ability to raise additional funding necessary to fund its business plans and continued operations; and the other factors discussed in OncoSec’s filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ended April 30, 2017.*

*Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.*

### CONTACT:

Investor Relations  
OncoSec Medical Incorporated  
855-662-6732  
[investors@oncosec.com](mailto:investors@oncosec.com)

Media Relations  
OncoSec Medical Incorporated  
855-662-6732  
[media@oncosec.com](mailto:media@oncosec.com)

---

